Immunoregulatory properties of erythroid nucleated cells induced from CD34+ progenitors from bone marrow.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
03
2023
accepted:
14
06
2023
medline:
3
7
2023
pubmed:
30
6
2023
entrez:
30
6
2023
Statut:
epublish
Résumé
CD 71+ erythroid nucleated cells have pronounced immunoregulatory properties in normal and pathological conditions. Many populations of cells with immunoregulatory properties are considered candidates for cellular immunotherapy for various pathologies. This study characterized the immunoregulatory properties of CD71+ erythroid cells derived from CD34-positive bone marrow cells under the influence of growth factors that stimulate differentiation into erythroid cells. CD34-negative bone marrow cells were used to isolate CD71+ erythroid nuclear cells. The resulting cells were used to assess the phenotype, determine the mRNA spectrum of the genes responsible for the main pathways and processes of the immune response, and obtain culture supernatants for the analysis of immunoregulatory factors. It was found that CD71+ erythroid cells derived from CD34+ cells carry the main markers of erythroid cells, but differ markedly from natural bone marrow CD71+ erythroid cells. The main differences are in the presence of the CD45+ subpopulation, distribution of terminal differentiation stages, transcriptional profile, secretion of certain cytokines, and immunosuppressive activity. The properties of induced CD71+ erythroid cells are closer to the cells of extramedullary erythropoiesis foci than to natural bone marrow CD71+ erythroid cells. Thus, when cultivating CD71+ erythroid cells for clinical experimental studies, it is necessary to take into account their pronounced immunoregulatory activity.
Identifiants
pubmed: 37390055
doi: 10.1371/journal.pone.0287793
pii: PONE-D-23-08362
pmc: PMC10313023
doi:
Substances chimiques
Antigens, CD34
0
Cell Adhesion Molecules
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0287793Informations de copyright
Copyright: © 2023 Shevchenko et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur Cytokine Netw. 2001 Apr-Jun;12(2):274-9
pubmed: 11399516
Cells. 2020 Feb 27;9(3):
pubmed: 32121014
Exp Hematol. 2019 Jul;75:11-20
pubmed: 31154069
Front Immunol. 2016 May 17;7:184
pubmed: 27242791
Genes (Basel). 2022 Jul 26;13(8):
pubmed: 35893070
J Immunol. 2018 Jun 15;200(12):4044-4058
pubmed: 29735482
PLoS One. 2015 Apr 10;10(4):e0123232
pubmed: 25860801
Haematologica. 2019 Sep;104(9):1689-1691
pubmed: 31473604
Stem Cell Reports. 2021 Mar 9;16(3):428-436
pubmed: 33581053
Blood. 2013 Apr 18;121(16):3246-53
pubmed: 23422750
Immunity. 2019 Apr 16;50(4):796-811
pubmed: 30995500
Blood. 2007 May 1;109(9):3839-48
pubmed: 17202317
Genomics. 2007 Nov;90(5):574-82
pubmed: 17764892
Transplant Rev (Orlando). 2015 Apr;29(2):53-9
pubmed: 25475045
Bull Exp Biol Med. 2007 Feb;143(2):218-21
pubmed: 17970206
Nature. 2013 Dec 5;504(7478):158-62
pubmed: 24196717
Eur Cytokine Netw. 1996 Dec;7(4):771-4
pubmed: 9010680
Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12868-12876
pubmed: 32457162
Cells. 2020 Mar 06;9(3):
pubmed: 32155728
Nat Med. 2018 Oct;24(10):1536-1544
pubmed: 30297899
Clujul Med. 2015;88(4):468-72
pubmed: 26732055
Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17413-8
pubmed: 19805084
Vet Res. 2011 Jul 29;42:89
pubmed: 21801407
Nat Biotechnol. 2002 May;20(5):467-72
pubmed: 11981559
Front Bioeng Biotechnol. 2020 Feb 05;8:43
pubmed: 32117924
Commun Biol. 2021 Dec 10;4(1):1384
pubmed: 34893694
BMC Cell Biol. 2004 Oct 18;5(1):39
pubmed: 15488155
J Immunol. 2017 Sep 15;199(6):2081-2095
pubmed: 28779022
Bull Exp Biol Med. 2000 Dec;130(12):1159-61
pubmed: 11276310
Blood. 2005 Feb 15;105(4):1484-91
pubmed: 15514013
Front Immunol. 2020 Jul 24;11:1608
pubmed: 32793236
Cancers (Basel). 2021 Feb 19;13(4):
pubmed: 33669537
J Inflamm Res. 2020 Jul 31;13:401-410
pubmed: 32801833
Stem Cell Reports. 2021 May 11;16(5):1165-1181
pubmed: 33979601
Stem Cell Rev Rep. 2022 Jun;18(5):1809-1821
pubmed: 35181867
Cancer Lett. 2021 Feb 28;499:85-98
pubmed: 33279623
Nat Immunol. 2022 Jul;23(7):1109-1120
pubmed: 35761081
Cells. 2021 Nov 03;10(11):
pubmed: 34831223
Pharmacol Ther. 2021 Dec;228:107927
pubmed: 34171326
Exp Hematol Oncol. 2021 Oct 29;10(1):50
pubmed: 34715921
J Clin Med. 2019 Dec 02;8(12):
pubmed: 31810354
FEBS J. 2018 Aug;285(16):2944-2971
pubmed: 29637711
Microbiol Spectr. 2022 Aug 31;10(4):e0173022
pubmed: 35943266
Cytokine. 2002 Feb 21;17(4):221-5
pubmed: 11991675
PLoS Biol. 2018 Dec 14;16(12):e2006649
pubmed: 30550561
Trends Immunol. 2005 Jul;26(7):360-6
pubmed: 15978522
Genes Cells. 2022 Jan;27(1):25-42
pubmed: 34837452
Stem Cells Dev. 2019 Dec 1;28(23):1540-1551
pubmed: 31595840
Mol Med. 2018 Mar 23;24(1):11
pubmed: 30134792
J Allergy Clin Immunol. 2003 Apr;111(4):677-90; quiz 691
pubmed: 12704343
J Immunol. 2006 Nov 15;177(10):6730-7
pubmed: 17082586
Immunity. 2005 Feb;22(2):259-70
pubmed: 15723813